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autografts, xenografts, noncorneal autologous tissues, and laboratory-made tissue constructs, as well as modifications to corneal
allografts, such as deep-freezing, glycerol-dehydration, gamma irradiation, and cross-linking. These alternative tissue carriers for
the B-KPro are discussed with special regard to safety, practicality, and cost for the developing world.
1. Introduction
The Boston keratoprosthesis (B-KPro) is an artificial cornea
that offers a viable solution for corneal transplant candidates
whoareathighriskforgraftfailuressuchasthosewithaprior
history of graft rejection, dry eyes, and severe neurotrophic
andautoimmunediseases.Itprovidesaclearvisualaxiswith-
out astigmatism and rapid visual recovery postoperatively.
It is the most widely used corneal prosthesis in the United
S t a t e sa n di nt h er e s to ft h ew o r l d[ 1]. The B-KPro has a
collar-button design with a front plate, stem, and back plate
of poly[methyl methacrylate] (PMMA) or titanium [2]. The
device is implanted into a corneal graft and then sutured into
the patient’s cornea as in standard penetrating keratoplasty
(Figure 1).TheBostontypeIprocedureisfavoredineyeswith
adequate tear secretion, whereas the type II B-KPro (with an
added anterior nub) is reserved for near-hopeless cases with
severedestructionoftheocularsurface,suchasend-stagedry
eye conditions and cicatricial diseases [3].
From a global perspective, the need for human corneas
farexceedssupply.Althoughcornealtissueisreadilyavailable
in many regions of the developed world with established eye
bank systems, this is not the case for other populations. In
many developing countries, cultural and religious concerns
limit organ donations [4, 5]. Furthermore, healthcare and
financial restrictions can be a major barrier: for example,
a donor cornea from an eye bank in the United States can
cost about $3,000 due to the need for microbial testing,
administration, and transport alone [6]. Thus, the lack of
human donor tissue at a reasonable cost is one of the largest
barriers to reducing blindness through either standard PK
or KPro implantation [7]. A long-term, safe, and inexpensive
alternative is clearly needed for the developing world.
W h yi si tn e c e s s a r yt ou s eac o r n e a lg r a fta sav e h i c l e
for the B-KPro? After all, several other artificial corneas,
proposed from other centers throughout history, have been
designedtobeimplanteddirectlyintotherecipient’sdiseased
corneawithoutusingagraftasacarrier .Theanswerliesinour
experience that a double-plated (collar-button) keratopros-
thesis design has advantages over designs where the optical
stem is anchored by a horizontal haptic (plastic, metal, tooth,
etc.) placed within or in front of the patient’s cornea. Accord-
ing to our results, positioning of the B-KPro’s back plate









membrane, provides better long-term retention than other
arrangements. Accepting this principle of positioning, we
have in the past tried to work out practical techniques for
direct insertion into the patient’s cornea without using a
graft but without success. Such approaches have been too
traumaticatsurgeryorresultedinearlytissuemelt.Therefore,
w eh a v eu s e dac o r n e a lg r a fta sav e h i c l ef o rt h ed e v i c es i n c e
the mid-1960s, with improved retention.
We are therefore exploring alternatives to fresh corneal
tissue for use as a keratoprosthesis carrier. This includes
physical alterations to increase storage time, such as deep-
freezing, glycerol-dehydration, gamma irradiation, or cross-
linking of tissue. Other substitutes may include corneal
autografts, xenografts, skin, cartilage, and tissue constructs.
This review identifies alternative tissue carriers suitable for
the developing world in terms of safety, practicality, and cost
effectiveness.
2. Carriers for the Boston Keratoprosthesis
In the developed world with high levels of health expen-
ditures and established eye banks, standard fresh corneal
allografts (preserved from 1 to 14 days) are preferred. Addi-
tionally, allografts allow assembly with the B-KPro on a
side table before opening the patient’s eye. This minimizes
the time the eye is open and risk of vitreous protrusion or
choroidal hemorrhage. But, in the developing world, issues
with cost, logistics, and administration of the donor graft are
very substantial.
One alternative is to modify the donor tissue in order
to lengthen storage time prior to use. It is known that an
allograft can be stored deep-frozen (thus nonviable) and
still be usable as a lamellar graft [8]. As a carrier for the
B-KPro, there was no demonstrable difference in clinical
outcomes between fresh and frozen donor materials in a
recentlargeseries[9].Deep-freezingdestroysallcornealcells
and should theoretically be less antigenic. Storing human
allogenic corneas in a hospital freezer is practical for the B-
KPro surgery locally, but transport remains a problem.
Asecondalternativemaybetousedehydratedratherthan
frozen corneal tissue, where shipment in a small vial is easy
and practical see Table 1. Dehydration is performed simply
b yr e p l a c i n gc o r n e a lw a t e rw i t hg l y c e r o la n dh a sl o n gb e e n
a standard technique in biology [10]. Glycerol-preservation
of donor corneal tissue has for many decades been used in
lamellar keratoplasty with satisfactory outcomes [11]. This
method extends the time that a cornea can be stored and can
thereby allow the use of tissue that would otherwise be dis-
carded on the basis of prolonged death-to-preservation time.
In 2008, the Eye Bank Association of America estimated that
the United States harvested over 92,000 corneas, including
30,000 that were deemed unsuitable for optical grafting. Of
these, approximately 25% could have been preserved with
glycerol and eventually used, increasing the cornea donor
poolby7,000–8,000tissuesannually[7].Ourexperiencewith
glycerol-storedcorneasinB-KProsurgeryhasbeenfavorable
but the corneas need to be rehydrated in saline for 30–
60 minutes before use; otherwise their leathery consistence
makes suturing difficult. Corneas dehydrated by freeze-
drying, rather than by glycerol, would be expected to have
similar qualities, but preparation and shipment would be
more cumbersome.
Corneal allografts can be modified in other ways. After
B-KPro implantation, graft necrosis, melt, and subsequent
leak can occur postoperatively, particularly in autoimmune
diseases, leading to calamities like retinal detachment or
infection. Pretreatment aimed at increasing resistance to
enzymatic digestion might help reduce the incidence. Cross-
linking corneas with the help of riboflavin plus UV-A light
has been shown to reduce corneal susceptibility to digestion
with collagenases [12]. Whether such modified corneal grafts
show increased long-term stability is presently the subject of
a clinical study.
Gamma irradiated human corneas, such as Visiongraft
Sterile Cornea, available from Tissue Banks International,
have recently been used in place of fresh donor corneas for
lamellar patch grafts [13]. They have also been used success-
fully as carriers for the B-KPro [14]. In our experience, these
grafts are thinner than a fresh graft but are still functional.
In addition, these corneas can be easily transported in a
vial at room temperature. However, as long as testing for
residual viruses is required, the cost remains high, and it
is questionable whether gamma irradiated corneas have any
advantage over glycerol-dehydrated tissue.
For countries with limited resources and no eye bank
administration,theuseofthepatient’ sowncornea(autograft)
hasobviousadvantages.Thegraftandhosttrephiningdiame-
ters will, by necessity, be the same. The B-KPro assembly willJournal of Ophthalmology 3
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have to take place on a side table with the patient’s eye open,
which should take a maximum of five minutes. In spite of
such relatively minor disadvantages, the benefits of low cost
and easy logistics are often overriding, and this approach is
in use in several countries. A recent pilot keratoprosthesis
programwasinitiatedinEthiopiaandSudanthatsuccessfully
used patients’ own corneas as carriers for the B-KPro [15].
While these results are promising, widespread adoption is
limited by the health of the presurgical cornea which must
not have any stromal melt, perforation, or infection. Often,
thecorneaistoodamagedandthintobeused.Complications
areapttooccurifcorneasareunabletoswellandfillthespace
between the B-KPro plates, compounded by a heightened
sensitivity to necrosis and melt in corneas severely damaged
from disease. Therefore, we recommend the patient’s own
corneaasacarrieronlywhenitisstillcapableofswellingand
is not too scarred, inflamed, or thin [15].
A thin and scarred cornea can be used as an autograft,
however, if covered by a large conjunctival flap [16]. Such a
flap should be mobilized vertically, from the temporal sclera,
with intact bases above and below. It should be moderately
thick and wide enough to fit loosely over the entire cornea. It
is important that all corneal epithelium be removed before
the flap is sutured down (with 10-0 nylon) to the limbus,
s ot h a tap u r ec o n n e c t i v et i s s u ei n t e r f a c ei sc r e a t e d .L e a v i n g
patches of epithelium behind would later result in epithelial
c y s t s .As m a l lc e n t r a lo p e n i n gc a nb em a d ei nt h efl a pa t
the end of surgery and will result in gradual retraction of
the conjunctival edge to the edge of the B-KPro front plate.
Such a flap is an effective way of covering the carrier cornea
with a much needed barrier of conjunctival epithelium and
subepithelialbloodvessels,ideallypreventinganysubsequent
tissuemelt.Athickflaphastheaddedbenefitthatitcanmake
soft contact lens wear unnecessary. The downside of such a
vertical conjunctival flap is that it makes the procedure more
complex by adding surgery time. Also, there are situations
where the conjunctiva is too thin and scarred down to be
mobilized.
A hypothetical carrier possibility would be to use an
extracorneal autologous tissue, such as skin. Thin, hairless
dermis can be harvested from behind the ears or elsewhere.
Likelyabasementmembrane(e.g.,amnion)betweenthegraft
and the back plate will be needed in order to block cells and
large proteins from entering the eye through the plate holes.
Such studies are presently being conducted in animals. Also,
v a r i o u sf o r m so fc a r t i l a g ei nt h eb o d ya r eb e i n ge x p l o r e da s
c a r r i e rg r a fts u b s t i t u t e ss h a p e di n t os u i t a b l ed i a m e t e ra n d
thickness as either autografts, allografts, or xenografts [17].
In prior studies, cartilage from sternum or ears has been
implanted in animal corneas [18, 19].
It is important to acknowledge that not only availability
and safety but also low cost is a requirement for B-KPro
carrier tissue in the developing world. For many patients,
neitherautograftsnorallograftsarefeasible,forcingustolook4 Journal of Ophthalmology
beyond those possibilities. One such possibility is xenografts
(tissuefromanotherspecies).Gammairradiatedporcineand
bovine heart valves, pericardium, and so forth have been
successfully used in humans for years. If corneas from such
animals, ubiquitous in barnyards all over the world, could
be tolerated in human eyes, the search for a suitable carrier
material would be over. The biological questions regarding
xenografts would be transplantation immunity and sterility.
Gamma irradiation reduces antigenicity and sterilizes the
tissue, making xenografts a real possibility for humans.
Xenotransplantation from pigs is appealing with respect
to the cornea, as there are many similarities to humans with
regards to refractive power, size, and tensile strength [20].
Recent genetic manipulation of pigs has led to the prospect
that the remaining immunological barriers will be overcome
[21]. Though there is less risk of rejection from genetically
manipulated pigs, the cost is still high and availability is
complex. The question of sterility is also of high importance
andwhethergammairradiation(25–35KGy)cankillnotonly
bacteria but also all viruses that can pose a potential threat
to the new host. If the surfaceo fs u c hax e n o g r a ftw o u l d
still be vulnerable to necrosis and melt, a conjunctival flap as
described above, should be protective. These hypotheses are
presently being tested by our group in animal experiments
[22].
Finally, laboratory-synthesized tissue constructs may be
an alternative carrier tissue. Sheets of collagen fibrils, mod-
e r a t e l yc r o s s - l i n k e d ,h a v eb e e ns u c c e s s f u l l yu s e da sl a m e l l a r
grafts in humans with keratoconus [23, 24]. Recent studies
on the safety and functionality of a biosynthetic cornea
f o u n dt h a ti ts u p p o r t e dt h ei n g r o w t ho fe n d o g e n o u sc e l l s
and nerves, as well as functions such as touch sensation,
development of tear film, and normal eye pressure [23, 25].
Theoretically, the use of such constructs would be very
attractive as costly microbiological testing would not be
necessary,manufacturingcostswouldlikelydeclineovertime
oncemassproduced,andshippingwouldbeeasy.Thepresent
difficulty seems to be making the constructs biocompatible,
thick, and cohesive enough for suturing into a recipient
cornea.
In addition to expanding available options for B-KPro
carrier tissue, efforts are under way to make the B-KPro
device more readily available for the developing world and
the postoperative care less expensive. New designs of the B-
KPro that are more cost-effective are under current develop-
ment. Low-cost bandage contact lenses of variable diameters
are recommended to be used with the B-KPro. Although
antibiotic prophylaxis is needed for life in a patient with a
B-KPro, simple and affordable antibiotic combinations are
suggested such as Polymyxin B + Trimethoprim sulfate daily
to diminish the financial burden of this approach.
3. Conclusion
Oftheestimatedworldwide4–10millionpeoplewithcorneal
blindness needing surgical rehabilitation, at least 80% live in
the developing world [5, 26]. For this underserved popula-
t i o n ,t h eB - K P r oi se x p e c t e dt op l a ya ni n c r e a s i n gr o l e .Th e
present surgical technique of implantation requires corneal
tissue as a carrier for the device—however, the high cost
and lack of availability constitute a severe hurdle in many
countries.Thereisthereforeanurgentneedtofindalternative
carrier tissues that must be inexpensive, readily available,
and safe. In this review, we have presented a number of
alternative options and their advantages and disadvantages
are discussed.
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